Biomed - her guidance was for $43 million this year (which she called back in August) so, her downgrades should be out of the picture. Much to her dismay she might actually have to upgrade in the next 6 months upon Aryplase NDA and next years '05 Aldurazyme sales. If GENZ can double this years sales next year (which in the earlyt stages is totally possible) that puts sales in the 80-88 million in '05 PLUS the 65 or so patients coming off the extension trials which is an additional 11-13 million depending on 175 or 200k number. So, close to $100 million in Aldurazyme sales in '05 right? It might actually be a blessing that we have so many patients on extenstion studies because a) the data from that may show that prolonged use of Aldurazyme increases lifespan in these patients, (i'll tell you why later but gotta wrap it up) b) sales will increase by an additional 28% because of them.